Annexon, Inc.
NASDAQ:ANNXBiotechnology
-$0.04 today
- Market cap
- $576.73M
- Beta
- 1.18
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.01
Volume 2.98M
Average 2.56M
ANNX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Annexon, Inc.NASDAQ: ANNX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows in line with its trailing trend
Q1 FY2026 depreciation & amortization of $539K rose 0.4% year over year, behind the +0.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.7% from the prior quarter. Over 3 fiscal years it compounded at +0.9% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +0.4% toward the trailing-twelve-month pace of +0.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 2.17M USD
- Year-over-year change
- +0.7%
- 4-year CAGR
- -10.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.17M | +0.7% |
| FY2024 | 2024-12-31 | 2.15M | +0.1% |
| FY2023 | 2023-12-31 | 2.15M | +2.0% |
| FY2022 | 2022-12-31 | 2.11M | -38.3% |
| FY2021 | 2021-12-31 | 3.41M | — |
Depreciation & Amortization vs competitors
How ANNX compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +0.9% is the 5th highest of 11, against a peer median of -6.3%.
- Over three fiscal years its annual growth of +0.9% compares with a peer median of +4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $10.17M USD | -10.7% | +6.1% | 9.7% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $3.53M USD | +5.4% | +140.9% | 47.7% |
| LTM Dec 2025 | CHF 2.5M CHF | +15.5% | +0.4% | 69.9% | |
| LTM Mar 2026 | $2.43M USD | +1.2% | +1.2% | 1.0% | |
| LTM Mar 2026 | $2.17M USD | +0.9% | +0.9% | — | |
| FY2025 | €1.07M EUR | -2.5% | +30.3% | — | |
| LTM Mar 2026 | $856K USD | +258.2% | +6.4% | 1.5% | |
| LTM Mar 2026 | $528K USD | -25.9% | -17.1% | 6.3% | |
| LTM Sep 2026 | $378K USD | -10.0% | +28.4% | 5.3% | |
| LTM Mar 2026 | €377.74K EUR | -20.5% | -12.3% | 1287.9% | |
| LTM Mar 2026 | $305K USD | -36.9% | +1.9% | 0.6% | |
| Peer median (excluding ANNX) | — | -6.3% | +4.0% | 6.3% | |
Competitors are the stored peer set for ANNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (130.32M) | (141.95M) | (134.24M) | (138.2M) | (206.69M) |
| Depreciation & Amortization | 3.41M | 2.11M | 2.15M | 2.15M | 2.17M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 18.52M | 18.18M | 19.43M | 16.42M |
| Change in Working Capital | 3.28M | 3.74M | (5.81M) | 6.36M | 4.23M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.86M | (287K) | (2.08M) | 4.94M | 4.49M |
| Other Working Capital | (575K) | 4.03M | (3.73M) | 1.43M | (261K) |
| Other Non-Cash Items | 17.52M | 1.28M | (1.43M) | (7.75M) | (2.49M) |
| Operating Cash Flow | (106.11M) | (116.31M) | (121.14M) | (118.01M) | (186.36M) |
| Capital Expenditures | (1.65M) | (6.53M) | (193K) | (15K) | (137K) |
| Acquisitions (Net) | 0 | (64.97K) | 0 | 0 | 0 |
| Purchases of Investments | (225.6M) | (113.2M) | (108.09M) | (583.93M) | (212.21M) |
| Sales of Investments | 139.02M | 178.17M | 178.98M | 365.15M | 402.4M |
| Other Investing Activities | 0 | 64.97K | 0 | 0 | 0 |
| Investing Cash Flow | (88.24M) | 58.44M | 70.7M | (218.8M) | 190.05M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.8M | 130.48M | 135.51M | 161.87M | 110.47M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | (1.86M) |
| Other Financing Activities | 0 | (7.57M) | 14K | (665K) | 238K |
| Financing Cash Flow | 1.8M | 122.91M | 135.52M | 161.21M | 108.86M |
| Effect of Forex Changes | (1.17M) | 1K | 5K | (15K) | 2K |
| Net Change in Cash | (193.72M) | 65.04M | 85.09M | (175.61M) | 112.55M |
| Free Cash Flow | (107.76M) | (122.84M) | (121.34M) | (118.02M) | (186.49M) |
Annexon, Inc.
NASDAQ:ANNX
Intrinsic Alpha fair value
Locked
Current Price
$3.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.